Neovasc Inc. (NASDAQ:NVCN) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Neovasc Inc. (NASDAQ:NVCN) lost -7.04 Percent and closed its previous trading session at $0.03. The stock traded with the average Volume of 88.8 Million at the end of last session.
The company reported its last earnings Actual EPS of $-0.06/share. While, the analyst predicted that the company could provide an EPS of $-0.07/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.01/share which shows an Earnings Surprise of 14.3 Percent.
Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Neovasc Inc. (NASDAQ:NVCN) as Buy, 0 analysts given Outperform signal, 1 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -28.49% where SMA50 and SMA200 are -60.11% and -95.61% respectively.
Neovasc Inc. (NASDAQ:NVCN) currently has a Weekly Volatility of 18.04% percent while its Monthly Volatility is at 13.92% percent. While talking about Performance of the Stock, Neovasc Inc. currently has a Weekly performance of -31.53%, monthly performance percentage is -33.82 percent, Quarterly performance is -88.81 percent, 6 months performance shows a percent value of -96.86% and Yearly Performance is -97.77 percent.
Neovasc Inc. is a specialty medical device company. It develops, manufactures and markets products for the cardiovascular marketplace. The Company’s products include the Tiara (TM) mitral valve prosthesis in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer (TM) for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products, including transcatheter heart valves. Neovasc Inc. is headquartered in Richmond, Canada.